Birgit Hirschmann
University of Regensburg
9 Papers
35 Citations
Birgit Hirschmann is an academic researcher from University of Regensburg. The author has contributed to research in topics: Tumor progression & Temozolomide. The author has an hindex of 7, co-authored 9 publications.
Chat about Author
Papers
RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma--a phase II study.
Christoph P. Beier,Christina Schmid,Thierry Gorlia,Christine Kleinletzenberger,Dagmar Beier,Oliver Grauer,Andreas Steinbrecher,Birgit Hirschmann,Alexander Brawanski,Christopher Dietmaier,Tanja Jauch-Worley,Oliver Kölbl,Torsten Pietsch,Martin Proescholdt,Petra Rümmele,Armin Muigg,G. Stockhammer,Monika E. Hegi,Ulrich Bogdahn,Peter Hau +19 more
TL;DR: Together, the investigated combination is tolerable and feasible and neither the addition of PEG-Dox nor the prolonged administration of Temozolomide resulted in a meaningful improvement of the patient's outcome as compared to the EORTC26981/NCIC-CE.3 data.
119
Transcranial electro-hyperthermia combined with alkylating chemotherapy in patients with relapsed high-grade gliomas: phase I clinical results
C. Wismeth,Christine Dudel,Christina Pascher,Paul Ramm,Torsten Pietsch,Birgit Hirschmann,Christiane Reinert,Martin Proescholdt,Petra Rümmele,Gerhard Schuierer,Ulrich Bogdahn,Peter Hau +11 more
TL;DR: EHT plus alkylating chemotherapy is tolerable in patients with relapse of high-grade gliomas and a Phase II trial targeting treatment effects is warranted on the basis of the results raised in this trial.
62
Pegylated liposomal doxorubicin in recurrent malignant glioma: analysis of a case series
Martin Glas,Horst J. Koch,Birgit Hirschmann,Tanja Jauch,Andreas Steinbrecher,Ulrich Herrlinger,Ulrich Bogdahn,Peter Hau +7 more
TL;DR: These data demonstrate the safety and moderate efficacy of PEG-DOX ± temozolomide therapy in recurrent malignant glioma and the potential of this nonalkylating chemotherapy should be further explored.
30
Tenascin-C protein is induced by transforming growth factor-beta1 but does not correlate with time to tumor progression in high-grade gliomas
Peter Hau,Leoni A. Kunz-Schughart,Petra Rümmele,Füsun Arslan,Anett Dörfelt,Horst J. Koch,Annette Lohmeier,Birgit Hirschmann,Adolf Müller,Ulrich Bogdahn,Anja-Katrin Bosserhoff +10 more
TL;DR: Induction of Tenascin-C by TGF-ß1 is described, possibly providing a mechanism for the invasion of high-grade gliomas into healthy parenchyma.
27
Maintenance therapy with 13-cis retinoid acid in high-grade glioma at complete response after first-line multimodal therapy--a phase-II study.
C. Wismeth,Peter Hau,Klaus Fabel,Ulrike Baumgart,Birgit Hirschmann,Horst J. Koch,Tanja Jauch,Oliver Grauer,Lisa Drechsel,Alexander Brawanski,Ulrich Bogdahn,Andreas Steinbrecher +11 more
TL;DR: A controlled clinical trial to test the efficacy of cRA as a maintenance treatment in malignant glioma is warranted after it was found that maintenance therapy with high-dose cRA is feasible and well tolerated over long periods of time.
24